Patent for J&J's Remicade invalidated, cheaper version looms

TRENTON, N.J. (AP) - A cheaper version of Johnson & Johnson's top-selling drug, the rheumatoid arthritis treatment Remicade, could be available in the U.S. two years early after a federal judge ruled a key patent on the drug invalid.